A phase 2, Proof of Concept Trial of AG-348 in Thalassemia.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs AG 348 (Primary)
- Indications Thalassaemia
- Focus Proof of concept; Therapeutic Use
- 14 Feb 2018 According to an Agios Pharmaceuticals media release, the company is planning to Initiate this study in fourth quarter of 2018.
- 12 Jan 2018 New trial record